We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

200 hedge funds and large institutions have $5.01B invested in Intercept Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 78 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 23

107% more capital invested

Capital invested by funds: $2.42B → $5.01B (+$2.58B)

47% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 53

18% more funds holding

Funds holding: 169200 (+31)

14% more call options, than puts

Call options by funds: $257M | Put options by funds: $225M

Holders
200
Holders Change
+31
Holders Change %
+18.34%
% of All Funds
5.33%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
54
Increased
78
Reduced
53
Closed
23
Calls
$257M
Puts
$225M
Net Calls
+$31.7M
Net Calls Change
+$71.9M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
126
Paloma Partners
Connecticut
$1.2M +$920K +4,249 New
OC
127
Oppenheimer & Co
New York
$1.16M -$586K -2,705 -40%
Canada Pension Plan Investment Board
128
Canada Pension Plan Investment Board
Ontario, Canada
$1.16M +$888K +4,100 New
SG Americas Securities
129
SG Americas Securities
New York
$1.15M -$361K -1,666 -29%
Tudor Investment Corp
130
Tudor Investment Corp
Connecticut
$945K +$725K +3,350 New
MCM
131
Mazama Capital Management
Oregon
$925K +$710K +3,279 New
JMPWA
132
JP Morgan Private Wealth Advisors
California
$910K +$699K +3,228 New
Public Employees Retirement Association of Colorado
133
Public Employees Retirement Association of Colorado
Colorado
$905K +$167K +773 +32%
AQR Capital Management
134
AQR Capital Management
Connecticut
$902K -$801K -3,700 -54%
IRF
135
IBM Retirement Fund
New York
$834K
3NC
136
300 North Capital
California
$736K +$3.03K +14 +0.5%
URS
137
Utah Retirement Systems
Utah
$705K +$65K +300 +14%
Janney Montgomery Scott
138
Janney Montgomery Scott
Pennsylvania
$684K +$170K +785 +48%
GGHC
139
Gilder Gagnon Howe & Co
New York
$657K -$7.08M -32,709 -93%
RIL
140
Rothschild Investment LLC
Illinois
$618K
WS
141
Wedbush Securities
California
$604K -$16.2K -75 -3%
Zurich Cantonal Bank
142
Zurich Cantonal Bank
Switzerland
$578K -$414K -1,914 -48%
DCM
143
DAFNA Capital Management
California
$564K -$4.31M -19,900 -91%
LCS
144
Levin Capital Strategies
New York
$564K +$433K +2,000 New
American Century Companies
145
American Century Companies
Missouri
$561K
NCCM
146
Nine Chapters Capital Management
New Jersey
$536K -$823K -3,800 -67%
HSBC Holdings
147
HSBC Holdings
United Kingdom
$522K +$401K +1,852 New
Bank of Montreal
148
Bank of Montreal
Ontario, Canada
$476K +$174K +802 +90%
Capital Fund Management (CFM)
149
Capital Fund Management (CFM)
France
$463K -$7.04M -32,518 -95%
Dimensional Fund Advisors
150
Dimensional Fund Advisors
Texas
$456K +$198K +914 +132%

ICPT Hedge Fund Activity: Q1 2015 in Review

200 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2015, worth a combined $5.01B — up 107% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new ICPT positions and 23 closed out — a net gain of 31 holders — while 78 added to existing stakes and 53 trimmed.

The largest buyer was Ameriprise, adding an estimated $161M. The largest seller was OrbiMed, cutting an estimated $79M.

  • 200 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2015, up from 169 in Q4 2014.
  • Funds reported $5.01B of Intercept Pharmaceuticals, Inc. stock for Q1 2015, up 107% quarter-over-quarter.
  • 54 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2015 and 23 closed out, a net change of +31 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2015 was Ameriprise, an estimated $161M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2015 was OrbiMed, an estimated $79M sold.

Based on aggregated 13F filings for Q1 2015.